SLS vs. TERN: Which Pharmaceutical Stock Offers Greater Potential as Merck Plans $6B Investment in Cancer Ahead of Keytruda Patent Expiration?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy SLS?
Source: stocktwits
Leukemia Therapies Advancements: SLS and TERN are making progress in leukemia therapies, with TERN-701 targeting chronic myeloid leukemia (CML) and SLS focusing on a maintenance immunotherapy for acute myeloid leukemia (AML), both expected to have Phase 3 readouts by 2026.
Market Sentiment Shift: Retail sentiment has shifted, with TERN moving to a bullish outlook while SLS has adopted a bearish stance, reflecting differing investor confidence in their respective stocks.
Financial Opportunities and Strategies: Merck anticipates a $70 billion commercial opportunity beyond Keytruda, as it prepares for the expected loss of exclusivity in 2028, while also expanding its newer Keytruda QLEX formulation.
Stock Performance and Analyst Ratings: SLS stocks have shown a significant upside potential, with a consensus rating of 'Strong Buy', while TERN's stock has also gained traction, reflecting a broader positive sentiment in the oncology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.990
Low
7.00
Averages
7.25
High
7.50
Current: 4.990
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dagco Increases Sellas Stake to 1.01% Ahead of Key Data
- Stake Increase: Dagco added 451,240 shares of Sellas Life Sciences on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million, making it the second-largest holding at 1.01% of its portfolio, indicating strong confidence in Sellas' future prospects.
- Clinical Data Catalyst: Sellas is set to present preclinical data on SLS009 at the AACR conference, targeting acute myeloid leukemia (AML), with lab studies showing that it induces leukemia cell death by enhancing caspase-3 activity, potentially offering new treatment options for AML patients.
- Regal Trial Progress: The Phase 3 Regal trial has recorded 72 survival events, moving closer to the 80-event threshold for final analysis, with the CEO suggesting that the slower accumulation of events may indicate longer patient survival, further heightening investor expectations.
- Optimistic Market Sentiment: Retail sentiment for SLS on Stocktwits is deemed 'extremely bullish' amid high message volume, with investors generally optimistic about the potential of SLS009, reflecting positive market expectations for Sellas' future developments.
See More
SLS and ATNM Present Key Data Catalysts Ahead of AACR Summit
- Optimistic Outlook for SLS009: Sellas is set to present preclinical AML data on SLS009 at the AACR meeting, demonstrating significant increases in cancer cell death in models with ASXL1 and TP53 mutations, which could attract investor attention and drive stock price appreciation.
- ATNM Data Highlights: Actinium will showcase new data from its Actinium-225 radiotherapy platform at AACR, particularly regarding ATNM-400 and Actimab-A across leukemia and solid tumor programs, potentially boosting market confidence in its treatment options.
- Analyst Target Discrepancies: According to consensus estimates from Koyfin, ATNM has a 12-month average analyst price target of $5.75, implying a 342% upside, while SLS's target is $8.67, suggesting about 66% upside, indicating a higher appeal for ATNM among investors.
- Retail Sentiment Comparison: On Stocktwits, retail sentiment for ATNM is deemed 'extremely bullish', while SLS appears 'bearish', which may influence investor decisions and market performance.
See More
Sellas Life Sciences Advances SLS009 Therapy for AML
- Mechanism Breakthrough: Sellas Life Sciences reported that SLS009 blocks key survival pathways in acute myeloid leukemia (AML) cells, making them more susceptible to natural programmed cell death, indicating significant therapeutic potential.
- Clinical Trial Progress: The company's late-stage trial for AML is advancing toward final analysis, expected to occur upon recording the 80th patient death, suggesting potential for extended survival with the therapy.
- Investor Sentiment Recovery: SLS stock saw retail sentiment shift from 'bearish' to 'neutral' over the past 24 hours, reflecting optimism among investors regarding upcoming clinical data and conference presentations, with shares rising 6%.
- Data Release Anticipation: Sellas is set to present preclinical data on SLS009 on April 21 at the conference, which is likely to attract further investor interest and potentially drive stock price increases.
See More
Copper Supply Shortage Intensifies, Salazar Resources Poised for Growth
- Copper Supply Deficit: A projected 600,000-tonne refined copper deficit for 2026 is driven by persistent mine disruptions and a supply chain that cannot keep pace, with prices expected to reach $12,000 per tonne by mid-2026 due to strong demand.
- Monja Project Advancements: Salazar Resources has identified a high-priority copper-gold porphyry target at its Monja Project in Ecuador, with rock sampling showing a best result of 4.77% copper and 1.12 g/t gold, indicating strong exploration potential that could become a cornerstone of the company's growth strategy.
- Acquisition of New Assets: The recent acquisition of four copper-gold exploration properties enhances Salazar's market position in Ecuador while retaining a 25% interest in the El Domo copper-gold mine, which is expected to commence production in July 2027, further solidifying the company's production capabilities.
- Construction Progress: Foran Mining's McIlvenna Bay project has reached approximately 91% completion and is on track for mid-2026 commercial production, indicating the company's critical role in supporting global energy transition and renewable energy development.
See More
AMEX SUSPENDS NEWS PENDING LST 9.270000
AMEX Halts Spending: American Express has paused its spending initiatives, indicating a shift in financial strategy.
Financial Impact: The decision to halt spending is expected to have significant implications for the company's financial performance and market position.
See More
Sellas to Present New SLS009 Data at AACR Meeting
- New Drug Data Presentation: Sellas is set to present new preclinical data on its CDK9 inhibitor SLS009 at the AACR meeting on April 21, revealing that the drug induces leukemia cell death by increasing caspase-3 activity and reducing survival proteins like MCL-1 and survivin, potentially offering new therapeutic avenues.
- Enhanced Drug Potency: Preclinical findings indicate that SLS009's potency increases with repeated exposure, with early effects appearing within hours and strengthening over 24 hours, a characteristic that may provide a competitive edge in treating resistant leukemia cases.
- Investor Focus on AML Study: Investor attention remains on the Phase 3 Regal trial evaluating GPS as maintenance therapy for AML patients, with 72 overall survival events recorded, nearing the 80-event threshold required for analysis, which could expedite result announcements.
- Market Sentiment Shift: Despite SLS stock surging 367% over the past year, retail sentiment has shifted from 'extremely bullish' to 'bearish', reflecting cautious market attitudes towards the upcoming survival data release, which may impact short-term stock performance.
See More
Dagco Increases Sellas Stake to 1.01% Ahead of Key Data
- Stake Increase: Dagco added 451,240 shares of Sellas Life Sciences on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million, making it the second-largest holding at 1.01% of its portfolio, indicating strong confidence in Sellas' future prospects.
- Clinical Data Catalyst: Sellas is set to present preclinical data on SLS009 at the AACR conference, targeting acute myeloid leukemia (AML), with lab studies showing that it induces leukemia cell death by enhancing caspase-3 activity, potentially offering new treatment options for AML patients.
- Regal Trial Progress: The Phase 3 Regal trial has recorded 72 survival events, moving closer to the 80-event threshold for final analysis, with the CEO suggesting that the slower accumulation of events may indicate longer patient survival, further heightening investor expectations.
- Optimistic Market Sentiment: Retail sentiment for SLS on Stocktwits is deemed 'extremely bullish' amid high message volume, with investors generally optimistic about the potential of SLS009, reflecting positive market expectations for Sellas' future developments.
See More
SLS and ATNM Present Key Data Catalysts Ahead of AACR Summit
- Optimistic Outlook for SLS009: Sellas is set to present preclinical AML data on SLS009 at the AACR meeting, demonstrating significant increases in cancer cell death in models with ASXL1 and TP53 mutations, which could attract investor attention and drive stock price appreciation.
- ATNM Data Highlights: Actinium will showcase new data from its Actinium-225 radiotherapy platform at AACR, particularly regarding ATNM-400 and Actimab-A across leukemia and solid tumor programs, potentially boosting market confidence in its treatment options.
- Analyst Target Discrepancies: According to consensus estimates from Koyfin, ATNM has a 12-month average analyst price target of $5.75, implying a 342% upside, while SLS's target is $8.67, suggesting about 66% upside, indicating a higher appeal for ATNM among investors.
- Retail Sentiment Comparison: On Stocktwits, retail sentiment for ATNM is deemed 'extremely bullish', while SLS appears 'bearish', which may influence investor decisions and market performance.
See More
Sellas Life Sciences Advances SLS009 Therapy for AML
- Mechanism Breakthrough: Sellas Life Sciences reported that SLS009 blocks key survival pathways in acute myeloid leukemia (AML) cells, making them more susceptible to natural programmed cell death, indicating significant therapeutic potential.
- Clinical Trial Progress: The company's late-stage trial for AML is advancing toward final analysis, expected to occur upon recording the 80th patient death, suggesting potential for extended survival with the therapy.
- Investor Sentiment Recovery: SLS stock saw retail sentiment shift from 'bearish' to 'neutral' over the past 24 hours, reflecting optimism among investors regarding upcoming clinical data and conference presentations, with shares rising 6%.
- Data Release Anticipation: Sellas is set to present preclinical data on SLS009 on April 21 at the conference, which is likely to attract further investor interest and potentially drive stock price increases.
See More
Copper Supply Shortage Intensifies, Salazar Resources Poised for Growth
- Copper Supply Deficit: A projected 600,000-tonne refined copper deficit for 2026 is driven by persistent mine disruptions and a supply chain that cannot keep pace, with prices expected to reach $12,000 per tonne by mid-2026 due to strong demand.
- Monja Project Advancements: Salazar Resources has identified a high-priority copper-gold porphyry target at its Monja Project in Ecuador, with rock sampling showing a best result of 4.77% copper and 1.12 g/t gold, indicating strong exploration potential that could become a cornerstone of the company's growth strategy.
- Acquisition of New Assets: The recent acquisition of four copper-gold exploration properties enhances Salazar's market position in Ecuador while retaining a 25% interest in the El Domo copper-gold mine, which is expected to commence production in July 2027, further solidifying the company's production capabilities.
- Construction Progress: Foran Mining's McIlvenna Bay project has reached approximately 91% completion and is on track for mid-2026 commercial production, indicating the company's critical role in supporting global energy transition and renewable energy development.
See More
AMEX SUSPENDS NEWS PENDING LST 9.270000
AMEX Halts Spending: American Express has paused its spending initiatives, indicating a shift in financial strategy.
Financial Impact: The decision to halt spending is expected to have significant implications for the company's financial performance and market position.
See More
Sellas to Present New SLS009 Data at AACR Meeting
- New Drug Data Presentation: Sellas is set to present new preclinical data on its CDK9 inhibitor SLS009 at the AACR meeting on April 21, revealing that the drug induces leukemia cell death by increasing caspase-3 activity and reducing survival proteins like MCL-1 and survivin, potentially offering new therapeutic avenues.
- Enhanced Drug Potency: Preclinical findings indicate that SLS009's potency increases with repeated exposure, with early effects appearing within hours and strengthening over 24 hours, a characteristic that may provide a competitive edge in treating resistant leukemia cases.
- Investor Focus on AML Study: Investor attention remains on the Phase 3 Regal trial evaluating GPS as maintenance therapy for AML patients, with 72 overall survival events recorded, nearing the 80-event threshold required for analysis, which could expedite result announcements.
- Market Sentiment Shift: Despite SLS stock surging 367% over the past year, retail sentiment has shifted from 'extremely bullish' to 'bearish', reflecting cautious market attitudes towards the upcoming survival data release, which may impact short-term stock performance.
See More
